{"id":"https://openalex.org/W2590932941","doi":"https://doi.org/10.1200/jco.2014.32.4_suppl.54","title":"Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC).","display_name":"Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC).","publication_year":2014,"publication_date":"2014-02-01","ids":{"openalex":"https://openalex.org/W2590932941","doi":"https://doi.org/10.1200/jco.2014.32.4_suppl.54","mag":"2590932941"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2014.32.4_suppl.54","doi":"https://doi.org/10.1200/jco.2014.32.4_suppl.54","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.4_suppl.54","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058325420","display_name":"Rana R. McKay","orcid":"https://orcid.org/0000-0002-0581-7963","observed_orcids":["https://orcid.org/0000-0002-0581-7963"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rana R. McKay","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007568796","display_name":"Kathryn P. Gray","orcid":"https://orcid.org/0000-0003-3287-3685","observed_orcids":["https://orcid.org/0000-0003-3287-3685"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathryn P. Gray","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103370030","display_name":"Julia H. Hayes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julia H. Hayes","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043769628","display_name":"Glenn J. Bubley","orcid":"https://orcid.org/0000-0002-3062-643X","observed_orcids":["https://orcid.org/0000-0002-3062-643X"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Glenn J. Bubley","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050435057","display_name":"Jonathan E. Rosenberg","orcid":"https://orcid.org/0000-0003-2637-4249","observed_orcids":["https://orcid.org/0000-0003-2637-4249"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan E. Rosenberg","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056766924","display_name":"Philip W. Kantoff","orcid":"https://orcid.org/0000-0001-7275-0597","observed_orcids":["https://orcid.org/0000-0001-7275-0597"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip W. Kantoff","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023517416","display_name":"Mary\u2010Ellen Taplin","orcid":"https://orcid.org/0000-0002-3384-0300","observed_orcids":["https://orcid.org/0000-0002-3384-0300"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary-Ellen Taplin","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"4_suppl","first_page":"54","last_page":"54"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9214000105857849,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9214000105857849,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":0.0714000016450882,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.8169999718666077},{"id":"https://openalex.org/keywords/biochemical-recurrence","display_name":"biochemical recurrence","score":0.9359999895095825},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9890000224113464},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/androgen-deprivation-therapy","display_name":"androgen deprivation therapy","score":1.0},{"id":"https://openalex.org/keywords/bicalutamide","display_name":"bicalutamide","score":0.8669999837875366},{"id":"https://openalex.org/keywords/gnrh-agonist","display_name":"GnRH agonist","score":0.9010000228881836},{"id":"https://openalex.org/keywords/prostate-specific-antigen","display_name":"prostate-specific antigen","score":0.6079999804496765},{"id":"https://openalex.org/keywords/psa-response","display_name":"PSA response","score":0.45899999141693115},{"id":"https://openalex.org/keywords/testosterone-recovery","display_name":"testosterone recovery","score":0.9020000100135803},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8410000205039978},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.5350000262260437},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.3630000054836273},{"id":"https://openalex.org/keywords/gleason-score-7","display_name":"Gleason score 7","score":0.5950000286102295},{"id":"https://openalex.org/keywords/radical-prostatectomy","display_name":"radical prostatectomy","score":0.847000002861023},{"id":"https://openalex.org/keywords/radiotherapy","display_name":"radiotherapy","score":0.7799999713897705},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5059999823570251},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.3720000088214874}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9159337282180786},{"id":"https://openalex.org/C2777899217","wikidata":"https://www.wikidata.org/wiki/Q4759439","display_name":"Androgen deprivation therapy","level":4,"score":0.7996176481246948},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7333900928497314},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6969359517097473},{"id":"https://openalex.org/C2777008409","wikidata":"https://www.wikidata.org/wiki/Q4914714","display_name":"Biochemical recurrence","level":5,"score":0.5699819326400757},{"id":"https://openalex.org/C2779279991","wikidata":"https://www.wikidata.org/wiki/Q6058681","display_name":"Testosterone (patch)","level":2,"score":0.5695908069610596},{"id":"https://openalex.org/C2780962315","wikidata":"https://www.wikidata.org/wiki/Q1988832","display_name":"Bicalutamide","level":5,"score":0.5488496422767639},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.5342065095901489},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.5249212384223938},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5245635509490967},{"id":"https://openalex.org/C2778043895","wikidata":"https://www.wikidata.org/wiki/Q1992653","display_name":"Goserelin","level":4,"score":0.498781681060791},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.4912707209587097},{"id":"https://openalex.org/C2781406297","wikidata":"https://www.wikidata.org/wiki/Q409450","display_name":"Prostate-specific antigen","level":4,"score":0.47686681151390076},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4270137548446655},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.4194398522377014},{"id":"https://openalex.org/C2779466945","wikidata":"https://www.wikidata.org/wiki/Q1765251","display_name":"Prostatectomy","level":4,"score":0.4014322757720947},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3486167788505554},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2550344467163086},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.20012500882148743},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.16375428438186646}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2014.32.4_suppl.54","doi":"https://doi.org/10.1200/jco.2014.32.4_suppl.54","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.4_suppl.54","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1564032187","https://openalex.org/W2066580649","https://openalex.org/W2567639533","https://openalex.org/W2598994374","https://openalex.org/W2116839245","https://openalex.org/W3163731137","https://openalex.org/W2056830343","https://openalex.org/W1997599033","https://openalex.org/W3029159925","https://openalex.org/W2590076073"],"abstract_inverted_index":{"54":[0],"Background:":[1],"Despite":[2],"primary":[3,122],"treatment":[4,32],"for":[5,54,61,204,282],"localized":[6],"PC,":[7],"20-30%":[8],"of":[9,24,33,49,73,83,92,101,111,119,127,136,170,232,296,306],"men":[10,34,55,65,189,209,221,290],"experience":[11],"a":[12,16,67,102,192,212,224,237],"BCR,":[13],"detected":[14],"by":[15],"rise":[17],"in":[18,285,288],"prostate-specific":[19],"antigen":[20],"(PSA).":[21],"Though":[22],"30%":[23],"these":[25],"patients":[26,128,171,178],"develop":[27],"metastatic":[28],"disease,":[29],"the":[30,47,125,168,201,205,304],"optimal":[31],"with":[35,56,66,167],"BCR":[36,57,68,283],"has":[37],"yet":[38],"to":[39,302],"be":[40],"determined.":[41],"In":[42],"this":[43,307],"trial,":[44],"we":[45],"evaluate":[46],"efficacy":[48,305],"DOC,":[50,278],"BEV,":[51,279],"and":[52,69,108,145,255,274,280],"ADT":[53,281],"after":[58,117,134,217,229,294],"local":[59],"therapy":[60,184],"PC.":[62],"Methods:":[63],"41":[64],"PSA":[70,141,161,202,238],"doubling":[71],"time":[72],"\u226410":[74],"months":[75],"(mos)":[76],"were":[77,245],"enrolled.":[78],"Patients":[79],"received":[80],"4":[81,258],"cycles":[82,91],"DOC":[84],"(75":[85],"mg/m2)":[86],"every":[87,96],"3":[88,97],"weeks,":[89,98],"8":[90],"BEV":[93],"(15":[94],"mg/kg)":[95],"18":[99],"mos":[100,110,216,228],"luteinizing-hormone":[103],"releasing":[104],"hormone":[105],"(LHRH)":[106],"agonist,":[107],"15":[109],"bicalutamide":[112],"(50":[113],"mg":[114],"daily)":[115],"beginning":[116],"completion":[118,135,295],"DOC.":[120],"The":[121,198,262],"endpoint":[123],"was":[124,150,157,164],"proportion":[126],"free":[129],"from":[130],"PSA-progression":[131],"1":[132,292],"year":[133,293],"ADT.":[137,219],"Secondary":[138],"endpoints":[139],"included":[140,268],"response,":[142],"testosterone":[143,194,214,226],"recovery,":[144],"toxicity.":[146],"Results:":[147],"Median":[148,153,160],"follow-up":[149,299],"27.6":[151],"mos.":[152],"age":[154],"at":[155,162,241],"diagnosis":[156,163],"58":[158],"years.":[159],"6.7":[165],"ng/mL,":[166],"majority":[169],"(59%)":[172],"having":[173],"Gleason":[174],"7":[175],"disease.":[176],"Most":[177],"underwent":[179],"radical":[180],"prostatectomy":[181],"+/-":[182],"radiation":[183],"(n=36).":[185],"At":[186],"baseline,":[187],"33":[188],"(81%)":[190],"had":[191,211,223,236],"normal":[193,213,225],"(>":[195],"240":[196],"ng/dL).":[197],"table":[199],"describes":[200],"responses":[203,287],"entire":[206],"cohort.":[207],"10":[208],"(28%)":[210],"6":[215],"completing":[218,230],"17":[220],"(47%)":[222],"12":[227],"ADT,":[231],"whom":[233],"5":[234],"(29%)":[235],"<0.2":[239],"ng/mL":[240],"that":[242],"time.":[243],"There":[244],"15%":[246],"grade":[247,250,253,257,265],"1,":[248],"34%":[249],"2,":[251],"39%":[252],"3,":[254],"12%":[256],"adverse":[259],"events":[260],"(AEs).":[261],"most":[263],"frequent":[264],"3-4":[266],"AEs":[267],"neutropenia":[269,272],"(24%),":[270],"febrile":[271],"(11%),":[273],"hypertension":[275],"(9%).":[276],"Conclusions:":[277],"resulted":[284],"complete":[286],"16":[289],"(44%)":[291],"therapy.":[297],"Longer":[298],"is":[300],"needed":[301],"determine":[303],"regimen.":[308],"Clinical":[309],"trial":[310],"information:":[311],"NCT00658697.":[312],"[Table:":[313],"see":[314],"text]":[315]},"counts_by_year":[{"year":2017,"cited_by_count":1}],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2017-03-03T00:00:00"}